Latest News

06/7/2022

1: Can you describe the central function of oligodendrocytes and myelin generation? Oligodendrocytes and neurons are types of brain cells. Neurons have a cell body that holds the nucleus (where the cell’s genes are located), dendrites that branch off from the cell body, and an axon that extends away from the cell body like a…

Read more
05/19/2022

Myrtelle augments pipeline with gene therapy for monogenic hearing loss, designed to repair and restore damaged cells and promote neuron survival Recent groundbreaking proof-of-concept animal studies show recovery of auditory function Technology also presents potential for an exciting platform for future hearing restoration therapies WAKEFIELD, Mass.–(BUSINESS WIRE)–Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical stage…

Read more
05/12/2022

Program further expands Myrtelle’s pipeline in white matter diseases leveraging proprietary vectors, constructs, capabilities and expertise to target oligodendrocytes and address the underlying cause of disorders involving myelin production. The gene therapy strategy uses a nonpathogenic recombinant adeno-associated virus (rAAV) as a vector to deliver a gene silencing microRNA (miRNA) directly to the central nervous…

Read more
04/20/2022

Nancy is grateful for her opportunity at Myrtelle, to help bring innovative therapies to patients with serious, incapacitating, and life-threatening genetic disorders. Nancy joined Myrtelle at its inception in 2021 and brings more than 25 years of experience in drug development. Nancy most recently served as Vice President, Head of Regulatory Affairs at Aruvant Sciences where she led the…

Read more
03/15/2022

WAKEFIELD, Mass.–(BUSINESS WIRE)–Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for its lead clinical-stage gene therapy, rAAV-Olig001-ASPA, for the treatment of…

Read more
03/11/2022

Armen Asatryan joined Myrtelle in 2021, shortly after its inception, and has over 20 years of combined experience in pharma/biotech, public health, and clini- cal medicine. Prior to joining the com- pany, Armen held positions of increasing responsibility at Abbott/AbbVie, AveXis/ Novartis, and most recently at AVROBIO, where he was Vice President of Clinical Development…

Read more